Influence
April 1, 2025

Medicare Beneficiary Receipt of Methadone by Drive Time to Opioid Treatment Programs

Kosali Simon, PhD

Published in JAMA Network Open. Here is a link to the article.

Regenstrief Institute authors: Kosali Simon, PhD, M.A.

This study examined how proximity to opioid treatment programs (OTPs) impacts methadone receipt among Medicare beneficiaries diagnosed with opioid use disorder (OUD) in 2020. Using Medicare claims and drive-time data, researchers found that methadone receipt decreased as distance to an OTP increased. Urban beneficiaries living within 5 minutes of an OTP were 54% more likely to receive methadone than those 15 minutes away; in rural areas, the drop was 27%. A threshold effect was observed at a 20-minute drive time, beyond which the likelihood of methadone receipt leveled off and showed minimal differences between urban and rural populations. The findings highlight the importance of OTP location in improving access to OUD treatment.

Authors

Jonathan Cantor 1, Helin G Hernandez 1, Aaron Kofner 2, Julie Lai 1, Denis Agniel 1, Kosali I Simon 3, Bradley D Stein 4, Erin A Taylor 1

Affiliations

1RAND, Santa Monica, California.

2RAND, Arlington, Virginia.

3O’Neill School of Public and Environmental Affairs, Indiana University, Bloomington.

4RAND, Pittsburgh, Pennsylvania.

Related News

infographic showing findings of study

Examining how insurance coverage shapes access to kidney transplantation

Regenstrief researchers contribute to a national study highlighting differences between Medicare Advantage and traditional Medicare  For people with kidney

Tarik Yuce, MD, Jiang Bian, PhD, Serena Guo, MD, PhD, Xing He, PhD, Yu Huang, PhD

GLP-1 medications linked to greater loss of regained weight after bariatric surgery

Study involving Regenstrief researchers uses real-world evidence to evaluate an option for managing weight recurrence  People who regain weight

image of a doctor consulting with a patient

Scalable approach could improve early detection of cognitive impairment in primary care

Regenstrief-led study evaluates how existing health data and patient-reported information could help clinicians identify individuals who need further assessmentEarly

Christopher Callahan, MD

Regenstrief Institute scientist named next president and CEO of Regenstrief Foundation 

Longtime Regenstrief investigator and former IU Center for Aging Research director will assume Foundation leadership in summer 2027.  Christopher